BUSINESSGUARDIAN US
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. The deal would combine AstraZeneca's nearly £196bn market value with BMS's $133bn valuation.
Mentioned
Related Signal
Adjacent reporting
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca said to have explored Bristol Myers merger
- AstraZeneca Said to Have Explored Bristol Myers Merger
- AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
- AstraZeneca Is Said to Have Explored Bristol Myers Merger